Diagenode

News

PRESS RELEASE - Diagenode and Alithea Genomics collaborate to offer scalable and affordable RNA-seq services
July 30, 2020

Diagenode expands services offering by introducing new high-throughput 3’mRNA sequencing service that utilizes MERCURIUS technology

Diagenode, a leading global provider of solutions for epigenetics research and sample preparation, has partnered with Alithea Genomics to provide a novel low cost, high performance 3’ mRNA-seq service to help advance transcriptomics research.

The new Alithea-powered technology, known as “MERCURIUS”, enables reliable gene expression quantification across the transcriptome with accurate differential analysis. The technology is highly scalable for large investigational studies, allowing the assessment of multiple conditions of interest or increasing statistical power underlying differential expression analysis with larger sets of replicates. The innovative barcoding approach supporting the new service makes the analysis of large cohorts of samples robust and cost efficient.

Diagenode brings deep expertise to commercializing this service for RNA researchers to help them to gain insight into processes such as cellular differentiation, carcinogenesis, transcription regulation and biomarker discovery among others. In addition to the company’s long history in developing advanced technologies for epigenomics services across DNA, RNA, and chromatin, Diagenode recently launched a unique D-Plex small RNA-seq library preparation solution for low inputs and high diversity as well as a bioinformatics data mining services - which addresses the challenge of analyzing RNA-seq data by applying machine learning, statistics, and database systems.

“The new Diagenode high-throughput 3’mRNA-seq service provides an excellent solution to identify genes that are differentially expressed in distinct cell populations, or in response to different treatments,” said Caroline Quoilin, Product Manager at Diagenode. “This service allows for the processing of a large number of samples simultaneously and will help researchers to investigate cell development mechanisms, to determine the molecular dysregulation that causes cancer and other diseases, and to study drug mode of action.”

Read more

Events

 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics